JPRN-C000000118未知未知
A Phase II Trial of Gefitinib Monotherapy in Elderly Chemo-naïve Patients with Advanced Non–Small Cell Lung Cancer - A Phase II Trial of Gefitinib Monotherapy in Elderly Chemo-naïve Patients with Advanced Non–Small Cell Lung Cancer
OGIK0 个研究点目标入组 60 人开始时间: 2005年9月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Past history of drug hypersensitivity SVC syndrome Pleural or pericardial effusion that required drainage Active infection Interstitial pneumonia or active lung fibrosis Symptomatic brain metastasis Active concomitant malignancy Uncontrolled diabetes Uncontrolled heart disease.
研究者
相似试验
已完成
2 期
A Phase II Study of Gefitinib Monotherapy as First-Line Treatment for Elderly Patients with Stage IIIB /IV Adenocarcinoma of the LungJPRN-UMIN000006144Central Japan Lung Study Group32
已完成
2 期
A Phase II study of Gefitinib as First-Line Treatment for Elderly Patients with Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.on-Small-Cell Lung CancerJPRN-UMIN000001863Central Japan Lung Study Group19
已完成
不适用
Phase I/II study of Gefitnib monotherapy as neo-adjuvant chemotherapy for cN2 lung adenocarcinoma with the EGFR mutatioJPRN-UMIN000004807KantoKoshinetsu lung cancer research group20
已完成
不适用
Analysis of Gefitinib(Drug) in lung cancer.CTRI/2017/05/008490Tata Memorial Hospital350
招募中
不适用
Efficacy and safety of gefitinib monotherapy for all types of refractory cancer patients with EGFR amplificatioKCT0004066Samsung Medical Center3